Get the Stockscreener App
3.725
2.63%
-0.075
Immix Biopharma Inc stock is traded at $3.725, with a volume of 732.46K.
It is down -2.63% in the last 24 hours and up +79.61% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$3.80
Open:
$3.79
24h Volume:
732.46K
Relative Volume:
1.77
Market Cap:
$108.27M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-4.0489
EPS:
-0.92
Net Cash Flow:
$-12.64M
1W Performance:
+9.14%
1M Performance:
+79.61%
6M Performance:
+76.61%
1Y Performance:
+132.70%
1-Day Range:
$3.41
$3.90
1-Week Range:
$3.40
$4.05
52-Week Range:
$1.34
$4.05
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
3.755 | 125.53M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.62 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.93 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.49 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.13 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immix Biopharma Inc Stock (IMMX) Latest News
How Immix Biopharma Inc. stock valuations compare to rivals2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
How to manage a losing position in Immix Biopharma Inc.Trade Exit Summary & Capital Efficient Trading Techniques - newser.com
Immix Biopharma to present NXC-201 trial data for AL amyloidosis at ASH - Investing.com
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - Investing News Network
Immix Biopharma (IMMX) ASH 2025 oral to feature NEXICART-2 first 20-patient data on Dec 7 - Stock Titan
Immix Biopharma Inc (IMMX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Immix Biopharma Inc. stock volume spike explainedJuly 2025 Reactions & Free Safe Capital Growth Stock Tips - newser.com
Why Immix Biopharma Inc. stock appeals to dividend seekersIPO Watch & Reliable Entry Point Alerts - newser.com
Can trapped investors hope for a rebound in Immix Biopharma Inc.Earnings Risk Summary & Reliable Trade Execution Plans - newser.com
Immix Biopharma Inc. stock trendline breakdownTrade Analysis Report & Daily Volume Surge Signals - newser.com
Comparing Immix Biopharma Inc. in custom built stock radarsQuarterly Portfolio Report & Reliable Breakout Forecasts - newser.com
Risk adjusted return profile for Immix Biopharma Inc. analyzedMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
How Immix Biopharma Inc. stock reacts to bond yieldsJuly 2025 Fed Impact & Precise Buy Zone Tips - newser.com
Is Immix Biopharma Inc. stock a smart buy before Fed meeting2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Is Immix Biopharma Inc. still worth holding after the dip2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Will Immix Biopharma Inc. see short term momentum2025 Major Catalysts & Capital Protection Trading Alerts - newser.com
Immix Biopharma (NASDAQ:IMMX) Trading Down 1.3%Time to Sell? - MarketBeat
What the charts say about Immix Biopharma Inc. todayMarket Sentiment Summary & Daily Profit Focused Stock Screening - newser.com
Momentum divergence signals in Immix Biopharma Inc. chartJuly 2025 Decliners & Daily Stock Trend Reports - newser.com
Immix Biopharma’s NXC-201 CAR-T Study: A Potential Game-Changer for AL Amyloidosis - TipRanks
Will Immix Biopharma Inc. stock sustain high P E ratios2025 Trade Ideas & Smart Swing Trading Techniques - newser.com
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):